Viking Therapeutics' Stock Plunges 42% Amid Debate Over Obesity Pill's Efficacy and Tolerability.

Viking Therapeutics' stock plunged 42% after disappointing Phase 2 obesity pill trial data. Analysts at Raymond James and William Blair call it a "Strong Buy" and "generational buying opportunity," while experts on X criticize the drug as "clearly inferior" to Eli Lilly's tirzepatide. The trial had a high dropout rate and concerns over tolerability.

Viking Therapeutics' stock experienced a significant drop of 42% on Tuesday following the release of Phase 2 trial data for its obesity pill, VK2735. The midstage trial, known as VENTURE-Oral, aimed to assess the drug's efficacy and tolerability in overweight and obese adults. The results, however, fell short of investor expectations, leading to a substantial sell-off in the company's shares.

The primary endpoint of the trial was met, with participants taking VK2735 achieving up to 12.2% mean weight loss over 13 weeks, compared to 1.3% in the placebo group. However, the high dropout rate of 28% due to gastrointestinal side effects, such as nausea and vomiting, raised concerns about the drug's tolerability. The side effect profile was worse than that observed in trials of Eli Lilly's oral drug, orforglipron, and Novo Nordisk's oral version of Wegovy.

Analysts at Raymond James and William Blair have called the situation a "Strong Buy" and a "generational buying opportunity," suggesting that the market may have overreacted to the trial results. However, experts on X have criticized the drug as "clearly inferior" to Eli Lilly's tirzepatide, citing the high dropout rate and concerns over tolerability.

The market reaction was swift and harsh, with Viking Therapeutics' market capitalization falling to just under $2.8 billion after the sell-off. Shares of other obesity-tied drugmakers, such as Eli Lilly and Novo Nordisk, saw a modest rise in response to the disappointing results.

Viking Therapeutics' VK2735 is designed to mimic the gut hormones GLP-1 and GIP to curb hunger and improve blood sugar markers. The drug is an oral GLP-1/GIP receptor agonist, making it more convenient than injectable treatments. However, the trial results have raised questions about the drug's long-term viability and competitive standing in the oral obesity market.

In conclusion, Viking Therapeutics' stock plunge following the Phase 2 trial data for VK2735 reflects a combination of efficacy concerns and high dropout rates due to gastrointestinal side effects. While some analysts see an opportunity in the market, the drug's competitive standing remains uncertain.

References:

[1] https://www.cnbc.com/2025/08/19/viking-therapeutics-obesity-pill-data.html
[2] https://www.investors.com/news/technology/viking-therapeutics-stock-weight-loss-pill-results/
[3] https://www.inkl.com/news/market-bloodbath-viking-therapeutics-stock-tanks-after-obesity-pill-side-effects-trigger-mass-dropouts